AusCann moves forward in cannabinoid hard shell capsules

Company News

by Rachael Jones

Cannabis company AusCann Group (ASX:AC8) has advanced the development of cannabinoid hard shell capsules.

They signed an agreement with PCI Pharma for the manufacture.

As they released their overview of their activities for the three months ending December 2018 they also showed that AusCann is on track for the production of cannabinoid medicines for use in clinical trials during this calendar year.

These medicines will be taken through the Company’s clinical development program for registration as an approved medical cannabis pain management pharmaceutical product.

The capsules will be targeted for sufferers of chronic and neuropathic pain, which in Australia alone account for 1.9 million people.

Shares in AusCann Group (ASX:AC8) are trading 1.55 per cent higher to 66 cents. 
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.